9-Hydroxyellipticine, Hydrochloride A potent topoisomerase II inhibitor

9-Hydroxyellipticine, Hydrochloride (CAS 52238-35-4)

9-Hydroxyellipticine, Hydrochloride | CAS 52238-35-4 is rated 5.0 out of 5 by 1.
  • y_2019, m_7, d_17, h_1
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_203940, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 86ms
  • REVIEWS, PRODUCT
Application: A potent topoisomerase II inhibitor
CAS Number: 52238-35-4
Purity: ≥95%
Molecular Weight: 298.8
Molecular Formula: C17H14N2O·HCL
Supplemental Information: This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

9-Hydroxyellipticine, Hydrochloride is a cell-permeable antitumor alkaloid that acts as a potent inhibitor of Topo II (IC50 = 3.3 μM). Restores functional wild-type p53 activity via inhibition of mutant p53 protein phosphorylation. Suppresses Cdk2 activity in a concentration-dependent manner. Also reported to inhibit telomerase activity in cultured pancreatic cells, possibly through inhibition of protein kinases. Binds to the aryl hydrocarbon receptor (AhR) in rat lung cytosol and inhibits aryl hydrocarbon hydroxylase (AHH) activity in rat hepatic microsomes


References

1. Renault, G. et al. 1987. Toxicol. Appl. Pharmacol. 89(2): 281-286. PMID: 3037729
2. Ohashi, M. et al. 1995. Jpn. J. Cancer Res. 86(9): 819-827. PMID: 7591958
3. Sato, N. et al. 1998. FEBS Lett. 441(2): 318-321. PMID: 9883907
4. Perry, P.J. et al. 1999. Anticancer Drug Des. 14(4): 373-382. PMID: 10625930
5. Sugikawa, E. et al. 1999. Anticancer Res. 19(4B): 3099-3108. PMID: 10652599
6. Mizumoto, K. et al. 2000. Cancer Lett. 149(1-2): 85-94. PMID: 10737712

Physical State :
Solid
Solubility :
Soluble in PBS, and water.
Storage :
Store at -20° C
Boiling Point :
557.7° C at 760 mmHg (Predicted)
IC50 :
topoisomerase II: IC50 = 3.3 µM
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
148569
SMILES :
CC1=C2C=CN=CC2=C(C3=C1NC4=C3C=C(C=C4)O)C.Cl

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 67ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Ohashi Ohashi, M. et al. (PubMed 7591958) found that ellipticine (sc-200878) and 9-Hydroxyellipticine (9HE), anti-tumor alkaloids that inhibit topoisomerase II, caused selective inhibition of p53 protein phosphorylation in Lewis lung carcinoma and SW480 in a concentration-dependent manner from 0.1 to 100 M. 9HE suppressed cdk2 kinase activity concentration-dependently from 1 to 100 M. -SCBT Publication Review
Date published: 2015-04-11
  • y_2019, m_7, d_17, h_1
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_203940, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 3ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.